Literature DB >> 20049680

[Cancer survival analysis in Germany--heading towards representative and comparable findings].

A Nennecke1, H Brenner, A Eberle, K Geiss, B Holleczek, J Kieschke, K Kraywinkel.   

Abstract

Cancer is an important issue within the German health care system with an estimated annual number of 435 000 incident cases and almost 210 000 deaths. Data of population-based cancer registries enable us to identify improvements of survival in oncological patients due to progress in therapeutic care and secondary prevention, as well as to investigate regional and international differences of this outcome. Comparing cancer survival rates, however, requires considering the impact of both methodical approaches and data quality. Potential factors of influence like algorithms, reference population, completeness of case ascertainment and quality of follow-up are discussed. For the first time harmonized proceedings are recommended in order to achieve comparability of population-based cancer survival rates in Germany. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 20049680     DOI: 10.1055/s-0029-1242772

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  3 in total

1.  Rural versus urban differences in end-of-life care for lung cancer patients in Germany.

Authors:  Julia Walter; Amanda Tufman; Reiner Leidl; Rolf Holle; Larissa Schwarzkopf
Journal:  Support Care Cancer       Date:  2018-02-04       Impact factor: 3.603

2.  Disease Management Project Breast Cancer in Hesse - 5-Year Survival Data: Successful Model of Intersectoral Communication for Quality Assurance.

Authors:  C Jackisch; A Funk; K König; D Lubbe; B Misselwitz; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

3.  Trends in cancer incidence and survival in the Augsburg study region-results from the Augsburg cancer registry.

Authors:  Nina Grundmann; Christa Meisinger; Martin Trepel; Jacqueline Müller-Nordhorn; Gerhard Schenkirsch; Jakob Linseisen
Journal:  BMJ Open       Date:  2020-08-30       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.